vs
Side-by-side financial comparison of FIRSTSUN CAPITAL BANCORP (FSUN) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
FIRSTSUN CAPITAL BANCORP is the larger business by last-quarter revenue ($110.0M vs $57.6M, roughly 1.9× Phathom Pharmaceuticals, Inc.).
FirstSun Capital Bancorp is a U.S.-headquartered financial holding company that offers a comprehensive range of banking and financial services, including commercial and consumer lending, deposit products, wealth management, and treasury solutions. It mainly serves individual customers, small and medium-sized enterprises, and corporate clients across U.S. regional markets.
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
FSUN vs PHAT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $110.0M | $57.6M |
| Net Profit | $21.6M | — |
| Gross Margin | — | 86.7% |
| Operating Margin | — | — |
| Net Margin | 19.6% | — |
| Revenue YoY | — | 94.1% |
| Net Profit YoY | -8.4% | 71.6% |
| EPS (diluted) | $0.76 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $110.0M | — | ||
| Q4 25 | $110.2M | $57.6M | ||
| Q3 25 | $107.3M | $49.5M | ||
| Q2 25 | $105.6M | $39.5M | ||
| Q1 25 | $96.2M | $28.5M | ||
| Q4 24 | $98.7M | $29.7M | ||
| Q3 24 | $98.2M | $16.4M | ||
| Q2 24 | $96.2M | $7.3M |
| Q1 26 | $21.6M | — | ||
| Q4 25 | $24.8M | — | ||
| Q3 25 | $23.2M | $-30.0M | ||
| Q2 25 | $26.4M | $-75.8M | ||
| Q1 25 | $23.6M | $-94.3M | ||
| Q4 24 | $16.4M | — | ||
| Q3 24 | $22.4M | $-85.6M | ||
| Q2 24 | $24.6M | $-91.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 87.5% | ||
| Q2 25 | — | 87.2% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 87.1% | ||
| Q3 24 | — | 85.6% | ||
| Q2 24 | — | 81.2% |
| Q1 26 | — | — | ||
| Q4 25 | 29.0% | — | ||
| Q3 25 | 26.4% | -30.8% | ||
| Q2 25 | 31.2% | -151.7% | ||
| Q1 25 | 30.9% | -276.5% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 29.1% | -433.0% | ||
| Q2 24 | 32.3% | -1055.4% |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 22.5% | — | ||
| Q3 25 | 21.6% | -60.5% | ||
| Q2 25 | 25.0% | -191.9% | ||
| Q1 25 | 24.5% | -330.7% | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 22.8% | -523.3% | ||
| Q2 24 | 25.5% | -1248.6% |
| Q1 26 | $0.76 | — | ||
| Q4 25 | $0.89 | — | ||
| Q3 25 | $0.82 | $-0.41 | ||
| Q2 25 | $0.93 | $-1.05 | ||
| Q1 25 | $0.83 | $-1.31 | ||
| Q4 24 | $0.57 | — | ||
| Q3 24 | $0.79 | $-1.32 | ||
| Q2 24 | $0.88 | $-1.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $413.7M | $130.0M |
| Total DebtLower is stronger | — | $209.1M |
| Stockholders' EquityBook value | $1.2B | $-438.2M |
| Total Assets | $8.6B | $259.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $413.7M | — | ||
| Q4 25 | $652.6M | $130.0M | ||
| Q3 25 | $659.9M | $135.2M | ||
| Q2 25 | $785.1M | $149.6M | ||
| Q1 25 | $621.4M | $212.3M | ||
| Q4 24 | $615.9M | $297.3M | ||
| Q3 24 | $573.7M | $334.7M | ||
| Q2 24 | $535.8M | $276.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $209.1M | ||
| Q3 25 | — | $207.1M | ||
| Q2 25 | — | $205.1M | ||
| Q1 25 | — | $203.2M | ||
| Q4 24 | — | $201.4M | ||
| Q3 24 | — | $175.7M | ||
| Q2 24 | — | $174.4M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $-438.2M | ||
| Q3 25 | $1.1B | $-422.5M | ||
| Q2 25 | $1.1B | $-405.8M | ||
| Q1 25 | $1.1B | $-338.4M | ||
| Q4 24 | $1.0B | $-253.6M | ||
| Q3 24 | $1.0B | $-187.1M | ||
| Q2 24 | $996.6M | $-233.8M |
| Q1 26 | $8.6B | — | ||
| Q4 25 | $8.5B | $259.1M | ||
| Q3 25 | $8.5B | $240.3M | ||
| Q2 25 | $8.4B | $250.2M | ||
| Q1 25 | $8.2B | $294.2M | ||
| Q4 24 | $8.1B | $378.3M | ||
| Q3 24 | $8.1B | $387.0M | ||
| Q2 24 | $8.0B | $319.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-166.8M |
| Free Cash FlowOCF − Capex | — | $-167.0M |
| FCF MarginFCF / Revenue | — | -290.0% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $111.5M | $-166.8M | ||
| Q3 25 | $49.4M | $-14.1M | ||
| Q2 25 | $15.0M | $-62.7M | ||
| Q1 25 | $26.4M | $-84.9M | ||
| Q4 24 | $101.1M | $-266.8M | ||
| Q3 24 | $48.1M | $-63.6M | ||
| Q2 24 | $20.9M | $-70.7M |
| Q1 26 | — | — | ||
| Q4 25 | $104.0M | $-167.0M | ||
| Q3 25 | $47.6M | $-14.1M | ||
| Q2 25 | $13.0M | $-62.8M | ||
| Q1 25 | $24.3M | $-84.9M | ||
| Q4 24 | $95.7M | $-266.9M | ||
| Q3 24 | $47.1M | $-63.6M | ||
| Q2 24 | $19.9M | $-70.8M |
| Q1 26 | — | — | ||
| Q4 25 | 94.3% | -290.0% | ||
| Q3 25 | 44.4% | -28.6% | ||
| Q2 25 | 12.3% | -159.0% | ||
| Q1 25 | 25.3% | -297.9% | ||
| Q4 24 | 97.0% | -899.8% | ||
| Q3 24 | 47.9% | -389.0% | ||
| Q2 24 | 20.6% | -966.2% |
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 0.4% | ||
| Q3 25 | 1.6% | 0.1% | ||
| Q2 25 | 1.9% | 0.2% | ||
| Q1 25 | 2.1% | 0.1% | ||
| Q4 24 | 5.5% | 0.5% | ||
| Q3 24 | 1.1% | 0.3% | ||
| Q2 24 | 1.1% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | 4.49× | — | ||
| Q3 25 | 2.13× | — | ||
| Q2 25 | 0.57× | — | ||
| Q1 25 | 1.12× | — | ||
| Q4 24 | 6.18× | — | ||
| Q3 24 | 2.15× | — | ||
| Q2 24 | 0.85× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FSUN
| Net Interest Income | $82.8M | 75% |
| Noninterest Income | $27.2M | 25% |
PHAT
Segment breakdown not available.
